Rupa Mazumder | Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Invention Awards

Best Researcher Award

Rupa Mazumder
Noida Institute of Engineering And Technology

Rupa Mazumder
Affiliation Noida Institute of Engineering And Technology
Country India
Scopus ID 7005832705
Documents 211
Citations 1,412
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0002-1888-548X

Rupa Mazumder is a researcher affiliated with the Noida Institute of Engineering And Technology, India, whose documented scholarly profile is associated with toxicology and pharmaceutical science. The supplied Scopus record reports 211 documents, 1,412 citations, and an h-index of 18, providing a bibliometric basis for considering the researcher within an academic recognition framework. [1]

Abstract

Rupa Mazumder is an India-based researcher affiliated with the Noida Institute of Engineering And Technology and associated with the subject area of Toxicology and Pharmaceutical Science. The supplied bibliometric profile records 211 scholarly documents, 1,412 citations, and an h-index of 18. These indicators provide measurable evidence of sustained research activity and scholarly visibility. Her profile is considered in relation to the Best Researcher Award under the International Invention Awards framework. Assessment of researcher recognition may consider publication productivity, citation influence, research continuity, subject expertise, and the broader relevance of scientific contributions. Bibliometric information should be interpreted alongside verified qualitative evidence and individual research outputs for balanced academic evaluation.

Keywords

Rupa Mazumder; Best Researcher Award; Toxicology; Pharmaceutical Science; Drug Research; Pharmacology; Research Impact; Scholarly Publications; Citation Analysis; h-index; Scientific Research; International Invention Awards.

Introduction

Researcher recognition in pharmaceutical and toxicological sciences commonly involves consideration of scholarly productivity, research quality, citation performance, and sustained engagement with scientific questions. Bibliometric indicators can provide a structured quantitative perspective, although they do not independently establish the originality or practical significance of individual studies. The available profile for Rupa Mazumder presents a substantial publication and citation record that can be examined as part of a broader academic assessment. [1] Standardized researcher identifiers such as Scopus Author ID and ORCID can also assist in distinguishing scholarly outputs and improving the reliability of attribution. [2]

Research Profile

The supplied profile identifies Rupa Mazumder with the Noida Institute of Engineering And Technology in India and places the research activity within Toxicology and Pharmaceutical Science. The reported Scopus Author ID is 7005832705, while the associated ORCID is 0000-0002-1888-548X. These persistent identifiers provide complementary mechanisms for connecting scholarly records with an individual researcher and can support verification across academic databases. [1] [2]

Research Contributions

Within toxicology and pharmaceutical science, research contributions may encompass the investigation of drug effects, safety, pharmacological mechanisms, toxicological responses, therapeutic development, and related biomedical questions. The available information does not provide a complete thematic inventory of Rupa Mazumder’s individual studies, so specific scientific claims should be based on verified publication records rather than inferred solely from bibliometric indicators. The documented publication volume nevertheless indicates sustained participation in scholarly research. [1]

Publications

The supplied Scopus information records 211 documents associated with the researcher profile. Publication counts are useful for describing research productivity but should be evaluated with attention to document type, authorship, journal quality, research field, chronology, and subject relevance. A complete publication assessment would require examination of the underlying indexed records and individual bibliographic metadata. The reported document count is therefore presented as a profile-level bibliometric indicator rather than as an independent measure of research quality. [1]

Research Impact

The supplied profile reports 1,412 citations and an h-index of 18. Citation indicators can help describe the visibility and scholarly uptake of published research, while the h-index combines productivity and citation dimensions into a single metric. Such measures vary across disciplines, career stages, database coverage, and publication practices and should therefore be interpreted within appropriate academic context. [1] Citation-based assessment is strongest when complemented by qualitative evidence concerning originality, methodological contribution, collaboration, and influence on subsequent research.

Award Suitability

The available bibliometric information provides a relevant quantitative foundation for consideration for the Best Researcher Award. The combination of 211 reported documents, 1,412 citations, and an h-index of 18 indicates an established scholarly record within the supplied profile. [1] Final award suitability should, however, be determined through verification of the researcher identity, publication record, research quality, originality, professional contributions, and alignment with the applicable award criteria. The profile therefore supports consideration without implying that bibliometric measures alone determine award outcome.

Conclusion

Rupa Mazumder’s supplied academic profile documents substantial scholarly activity in the field of Toxicology and Pharmaceutical Science, with 211 documents, 1,412 citations, and an h-index of 18. These indicators establish a useful quantitative basis for academic recognition while requiring contextual interpretation. [1] Verification through persistent researcher identifiers, indexed publications, and qualitative evidence can strengthen the assessment. On the information provided, the profile presents a credible basis for consideration under the Best Researcher Award category of the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rupa Mazumder, Author ID 7005832705. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005832705
  2. ORCID. (n.d.). ORCID record: Rupa Mazumder, ORCID 0000-0002-1888-548X. ORCID.
    https://orcid.org/0000-0002-1888-548X
  3. Journal article. (2026).Preparations, Applications, Patents, and Marketed Formulations of Nanoemulsions – A Comprehensive Review.
    http://dx.doi.org/10.2174/0122117385325186240912110731
  4. Journal article. (2025). A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease.
    https://doi.org/10.18311/jnr/2025/49903
  5. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/

Shiva Vairale | CSIR – National Chemical Laboratory | Best Researcher Award

Published on by Invention Awards

Best Researcher Award

Shiva Vairale
CSIR – National chemical Laboratory

Shiva Vairale
Affiliation CSIR – National Chemical Laboratory
Country India
Scopus ID 60050407800
Documents 6
Citations 9
h-index 3
Subject Area Drug Discovery
Event International Invention Awards
Google Scholar Rgn4SCoAAAAJ

Shiva Vairale is a researcher affiliated with the CSIR – National Chemical Laboratory in India, with research interests associated with biochemical sciences and drug discovery. Publicly indexed research records connect his work with bioactive molecules, natural products, biological macromolecules, antimicrobial investigations, and pharmacological applications. His research activities include collaborative studies addressing biologically relevant compounds and their potential therapeutic significance. Available publication records identify contributions to peer-reviewed research involving sericin-based nanotherapeutics and insect-derived metabolites, illustrating an interdisciplinary orientation spanning biochemistry, pharmacology, and translational drug-discovery research. [1]

Abstract

Shiva Vairale is a researcher at CSIR – National Chemical Laboratory whose documented work focuses on biochemical sciences, natural bioactive compounds, and drug discovery. His research profile includes investigations of biologically active molecules, therapeutic mechanisms, antimicrobial activity, and emerging nanotherapeutic approaches. Published work has addressed sericin-based formulations for anti-urolithiatic and antibacterial applications, while a recent review examines insect-derived metabolites and their pharmacological potential in modern drug discovery. These studies reflect an interdisciplinary research direction connecting biochemistry, natural products, pharmacology, molecular mechanisms, and translational applications. His indexed research record provides measurable indicators of scholarly activity and citation-based visibility.

Keywords

Shiva Vairale, Best Researcher Award, drug discovery, biochemical sciences, natural products, insect-derived metabolites, pharmacology, bioactive compounds, sericin nanotherapeutics, antimicrobial research, therapeutic applications, CSIR-National Chemical Laboratory, India.

Introduction

Drug discovery increasingly integrates natural-product chemistry, molecular biology, pharmacology, and advanced formulation strategies to identify biologically useful compounds. Within this multidisciplinary landscape, Vairale’s documented research is associated with the investigation of bioactive substances and their therapeutic relevance. His work at CSIR-National Chemical Laboratory places these activities within an established Indian research environment focused on chemical and biological sciences. [2] Recent publications further demonstrate engagement with natural metabolites and biological macromolecules as potential sources of pharmacological applications. [3]

Research Profile

Vairale’s research profile is situated primarily within biochemical sciences and drug discovery. Publicly available institutional and bibliographic information associates him with the Biochemical Sciences Division of CSIR-National Chemical Laboratory and with research involving bioactive compounds, biological assays, natural metabolites, and therapeutic applications. His academic record also places his doctoral research within biological sciences, supporting an interdisciplinary trajectory connecting chemical and biological investigation. [2]

Research Contributions

A documented contribution involves research on sericin-based nanotherapeutics, examining sericin and related nanoparticle formulations for anti-urolithiatic and antibacterial applications. The study combines biological macromolecules, nanotechnology, characterization, and pharmacological assessment. [1] Another contribution is a review of insect-derived metabolites in drug discovery, covering chemically diverse metabolites and their biological mechanisms while considering their translational relevance to pharmacotherapy. [4]

Publications

Vairale has contributed to peer-reviewed publications spanning natural products, biological macromolecules, antimicrobial research, and drug discovery. A notable publication is Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications, published in the International Journal of Biological Macromolecules in 2025 with DOI 10.1016/j.ijbiomac.2025.146763. [1] His 2026 review, Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges, appeared in Pharmacological Research – Natural Products, DOI 10.1016/j.prenap.2026.100808. [4]

Research Impact

The research addresses scientific questions relevant to therapeutic discovery, particularly the identification and characterization of biologically active substances. Work on sericin-based systems explores potential applications against urolithiasis and bacterial activity, while research concerning insect metabolites considers their broader pharmacological potential. These themes are relevant to continuing efforts to identify new biological resources and mechanisms for therapeutic development. The supplied bibliometric profile records six documents, nine citations, and an h-index of three. [1]

Award Suitability

For recognition under a Best Researcher Award category, the documented record provides evidence of peer-reviewed research activity, interdisciplinary subject engagement, and identifiable contributions to drug-discovery research. Relevant evidence includes publications involving biological macromolecules and natural metabolites, collaboration across research groups, and indexed bibliometric indicators supplied for this profile. The award record should be considered alongside the complete nomination materials and applicable evaluation criteria of the International Invention Awards. [5]

Conclusion

Shiva Vairale’s documented research activity reflects an interdisciplinary focus on biochemical sciences and drug discovery, with published work addressing sericin-based nanotherapeutics and insect-derived metabolites. His research connects natural bioactive resources with pharmacological investigation and potential therapeutic applications. The available bibliometric information and publication record provide a structured basis for describing his scholarly profile and its relevance to research recognition within the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus Author Details: Author ID 60050407800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60050407800
  2. Review article. (2026). Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges.
    https://doi.org/10.1016/j.prenap.2026.100808
  3. Research article. (2025). Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications.
    https://doi.org/10.1016/j.ijbiomac.2025.146763
  4. Google Scholar. (n.d.). Google Scholar author profile: Shiva Vairale. Google Scholar.
    https://scholar.google.com/citations?hl=en&user=Rgn4SCoAAAAJ
  5. International Invention Awards. (2026). International Invention Award.
    https://inventionawards.org/

Stephen Chelko | Toxicology and Pharmaceutical Science | Innovative Research Award

Published on by Invention Awards

Innovative Research Award

Stephen Chelko
Florida State University College of Medicine

Stephen Chelko
Affiliation Florida State University College of Medicine
Country United States
Scopus ID 54973874200
Documents 47
Citations 1,649
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0003-1675-5945

Stephen Chelko is a researcher affiliated with the Florida State University College of Medicine whose documented scholarly profile is associated with toxicology and pharmaceutical science. Available bibliometric information records 47 documents, 1,649 citations, and an h-index of 18, providing a quantitative basis for assessing research visibility and scholarly influence. [1]

Abstract

Stephen Chelko is a researcher associated with Florida State University College of Medicine and the fields of toxicology and pharmaceutical science. His indexed scholarly record comprises 47 documents, 1,649 citations, and an h-index of 18, according to the supplied Scopus profile information. These indicators provide a measurable basis for describing his research visibility and citation impact within scholarly databases. His profile may be considered in the context of recognition for innovative research, particularly where scientific investigation, translational relevance, and contribution to biomedical knowledge are central criteria. The Innovative Research Award provides a framework for highlighting documented scholarly achievement and research significance.

Keywords

Stephen Chelko; Innovative Research Award; toxicology; pharmaceutical science; biomedical research; Florida State University College of Medicine; research impact; scholarly publications; citation analysis; translational science.

Introduction

Academic recognition commonly considers the quality, relevance, originality, and influence of a researcher’s scholarly work. In this context, Stephen Chelko’s documented profile combines research activity in toxicology and pharmaceutical science with measurable bibliometric indicators. The available Scopus record identifies 47 documents, 1,649 citations, and an h-index of 18. [1]

Research Profile

Chelko’s stated subject area is Toxicology and Pharmaceutical Science, positioning his scholarly profile within disciplines concerned with biological effects, therapeutic development, pharmaceutical research, and related biomedical questions. His affiliation with Florida State University College of Medicine further places this work within an academic medical environment. [4]

Research Contributions

The available information supports describing Chelko’s contribution through his documented publication record and citation footprint rather than assigning unsupported claims about individual discoveries. Forty-seven indexed documents indicate sustained scholarly output, while the recorded citation count suggests that his published research has been referenced by subsequent academic literature. [1]

Publications

The supplied researcher profile reports 47 documents indexed in Scopus. Because complete publication titles, journals, publication years, and article-level DOI information were not supplied, this page does not attribute individual papers or DOI records without verification. The Scopus author profile provides the appropriate source for reviewing the complete indexed publication record. [1]

Research Impact

Research impact can be assessed through several complementary dimensions, including scholarly citations, publication continuity, disciplinary relevance, and potential contribution to scientific practice. Chelko’s reported 1,649 citations and h-index of 18 provide quantitative indicators of scholarly visibility, although bibliometric measures should be interpreted alongside qualitative assessment of research originality and significance. [1]

Award Suitability

The documented research profile is relevant to an Innovative Research Award because it demonstrates sustained scholarly activity in a biomedical subject area and a measurable citation record. Final award suitability should nevertheless depend on the official nomination criteria, verified publications, originality of contributions, supporting evidence, and independent evaluation by the responsible award committee. [5]

Conclusion

Stephen Chelko’s supplied academic profile presents a researcher working in toxicology and pharmaceutical science, affiliated with Florida State University College of Medicine. The reported record of 47 documents, 1,649 citations, and an h-index of 18 provides a measurable foundation for academic recognition. These indicators should be considered together with verified research quality and innovation.

References

  1. Elsevier. (n.d.). Scopus author details: Stephen Chelko, Author ID 54973874200. Scopus.
    https://www.scopus.com/pages/authors/54973874200
  2. ORCID. (n.d.). Stephen Chelko, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0003-1675-5945
  3. Google Scholar. (n.d.). Stephen Chelko — Google Scholar profile.
    https://scholar.google.com/citations?hl=en&user=5Hq6SM0AAAAJ
  4. Journal article. (2019.). Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.
    https://doi.org/10.1161/CIRCULATIONAHA.119.040676
  5. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

Lee Jia | Pharmacy | Research Excellence Award

Published on by Invention Awards

Prof. Lee Jia | Pharmacy | Research Excellence Award

Distinguished Professor and Director in Henan University, United States

Prof. Lee Jia is a highly accomplished pharmacologist with a strong academic foundation, earning his Ph.D. in Pharmacology from the State University of New York under Nobel Laureate Robert F. Furchgott and completing postdoctoral research at Duke University Medical Center in Durham, North Carolina. He currently serves as Distinguished Professor at The First Affiliated Hospital of Henan University and has held key leadership roles including Director of the Marine Drug R&D Center at Minjiang University and founding director of a cancer metastasis research center at Fuzhou University. His international career includes senior scientific positions at the National Cancer Institute, National Institutes of Health, and collaborations with institutions such as University of Geneva and Technological University Dublin. He is widely recognized for contributions to pharmacology, toxicology, nanomedicine, and cancer research, earning distinctions such as Fellow of the American Association of Pharmaceutical Scientists, Fellow of the Academy of Toxicological Sciences, and selection among the world’s top 2% scientists by Stanford University and Elsevier. He has received numerous prestigious honors including major national innovation awards in China, international research recognitions, and leadership roles in scientific societies such as the Chinese Pharmaceutical Association. In addition to his research impact, he has made extensive contributions as an editor, reviewer, and scientific organizer across leading journals and global conferences, shaping advancements in drug discovery and translational medicine.

Citation Metrics (Scopus)

15000
12000
9000
6000
3000
100
0

Citations
13224

Documents
226

h-index
55

Citations

Documents

h-index

View Scopus Profile

Featured Publications

 

Zsuzsanna Suba | Cancer research | Breakthrough Research Award

Published on by Invention Awards

Prof. Dr. Zsuzsanna Suba | Cancer research | Breakthrough Research Award

National Institute of Oncology, Budapest, Hungary

Profile

Orcid

🎓 Early Academic Pursuits

Prof. Dr. Zsuzsanna Suba embarked on her academic journey at the Semmelweis University of Medicine, earning her Doctor of Medicine in 1971. Her early interest in both general and oral pathology led her to pursue multiple certifications: Board certification in Pathology (1975), Dentistry and Stomatology (1986), and Oral Pathology (Sheffield, UK, 1987). She further advanced her academic credentials by completing a Ph.D. in 1994 and attaining the Habilitated Medical Science (Habil.Med.Sci.) degree in 2004, marking her as a leading expert in her field.

🩺 Professional Endeavors

Prof. Suba's career commenced in 1971 as an Assistant Professor at the 1st Institute of Pathology and Experimental Cancer Research at her alma mater. She then led the Oral Pathology Division within the Department of Oral and Maxillofacial Surgery at Semmelweis University from 1982 to 2011. In 2004, she was officially named Professor of Oral Pathology. Her final academic post was at the National Institute of Oncology, where she served as Professor of Pathology from 2011 until becoming Professor Emeritus in 2017, reflecting her decades-long contribution to academic medicine.

🧬 Contributions and Research Focus

Prof. Suba’s research has significantly shaped understanding in several niche yet vital domains of pathology. Her early work investigated cell proliferation kinetics and virus-induced experimental tumors. She later pioneered studies into the pathology of bone replacement in the oral and maxillofacial region, and the clinical and pathological evaluation of chemotherapy outcomes in oral cancers. Notably, she explored the correlations between metabolic disorders (like type-2 diabetes, insulin resistance, and obesity) and cancer incidence, particularly oral and breast cancers. Her groundbreaking research highlighted the hormonal mechanisms involved in tumor progression, the role of estrogen signaling in cancer risk, and even proposed a genome-stabilizing therapeutic model for breast cancer cases.

🌍 Impact and Influence

Prof. Suba’s research has had a substantial impact on the epidemiological and hormonal understanding of cancer biology, especially in women’s health. Her bold interpretations of the paradoxes in antiestrogen treatments in breast cancer, and her promotion of causal therapy over symptomatic treatment, have sparked meaningful discourse in oncological and hormonal therapy communities. Her findings bridge molecular biology, pathology, endocrinology, and clinical practice, positioning her as a multidisciplinary influencer in medical science.

📈 Academic Citations and Publications

With 128 peer-reviewed articles accumulating a total impact factor of 122.647, Prof. Suba has maintained a strong presence in the scientific literature. She has authored 12 books, 42 book chapters—many in English—and accumulated 1,230 independent citations as a first or last author. These achievements speak volumes about the relevance and longevity of her scientific contributions.

🖥️ Technical and Research Skills

Her academic career has been deeply rooted in molecular and surgical pathology techniques, including histopathological diagnostics, tumor cell kinetic analysis, and clinical trials of chemotherapy and hormone therapy outcomes. Her interdisciplinary acumen allows her to integrate pathology, biochemistry, endocrinology, and epidemiology in both laboratory and clinical research contexts.

👩‍🏫 Teaching Experience and Recognition

A beloved educator, Prof. Suba has been honored multiple times for her teaching excellence. She received the Teacher’s Award from Semmelweis University (1998) and again in 2008, this time chosen directly by students. She is known for her dedicated mentorship, ability to simplify complex medical content, and commitment to fostering critical thinking in future clinicians and researchers.

🏅 Honors and Awards

Throughout her illustrious career, she has been decorated with prestigious awards such as the MOTESZ Award for Young Researchers (1976), the Markusovszky Award (1993), and the recent Distinguished Cancer Treatment Innovation Award (2024) from Scifax. These accolades recognize both her innovative research and her lifelong dedication to cancer pathology.

🌟 Legacy and Future Contributions

Now serving as Professor Emeritus, Prof. Suba remains a venerated figure in oncology and pathology. Her visionary work on hormonal and metabolic links to cancer continues to guide current investigations. Her legacy lies not only in her scientific outputs but also in the inspired careers of countless students and clinicians she mentored. Her genome-stabilization framework offers a promising direction for personalized cancer therapy, and future researchers will undoubtedly build upon her foundational insights for decades to come.

Selected Publications

  • Suba Zsuzsanna (2024)
    DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care
    Cancers (Basel), 16(8):1573. April 19, 2024.

  • Suba Zsuzsanna (2024)
    Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus‑Faced Manner
    Current Oncology, 31(9):4885–4907. August 24, 2024.

  • Suba Zsuzsanna (2023)
    Rosetta Stone for Cancer Cure: Comparison of the Anticancer Capacity of Endogenous Estrogens, Synthetic Estrogens and Antiestrogens
    Oncology Reviews, 17:10708 (eCollection). April 19, 2023.

  • Suba Zsuzsanna (2020)
    Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen‑Responsive Cancer Cells via Activating Mutations
    Journal of Oncology & Therapy (or equivalent publication). 2020.

  • Suba Zsuzsanna (2018)
    Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
    Recent Patents on Anticancer Drug Discovery, 13(4):428–444. 2018.